S&P 500   4,298.30 (-0.03%)
DOW   33,563.55 (-0.31%)
QQQ   360.05 (+0.57%)
AAPL   171.70 (+0.59%)
MSFT   317.94 (+1.37%)
META   304.76 (+0.26%)
GOOGL   131.87 (-0.33%)
AMZN   127.76 (+1.41%)
TSLA   251.87 (+2.23%)
NVDA   436.98 (+1.41%)
NIO   9.04 (+1.46%)
BABA   87.04 (+1.75%)
AMD   104.07 (+1.27%)
T   15.00 (-0.07%)
F   12.54 (-0.16%)
MU   68.05 (+4.37%)
CGC   0.80 (-1.19%)
GE   110.46 (-1.67%)
DIS   80.89 (+0.95%)
AMC   8.06 (+3.47%)
PFE   33.02 (+2.90%)
PYPL   58.63 (+0.77%)
NFLX   377.72 (+0.36%)
S&P 500   4,298.30 (-0.03%)
DOW   33,563.55 (-0.31%)
QQQ   360.05 (+0.57%)
AAPL   171.70 (+0.59%)
MSFT   317.94 (+1.37%)
META   304.76 (+0.26%)
GOOGL   131.87 (-0.33%)
AMZN   127.76 (+1.41%)
TSLA   251.87 (+2.23%)
NVDA   436.98 (+1.41%)
NIO   9.04 (+1.46%)
BABA   87.04 (+1.75%)
AMD   104.07 (+1.27%)
T   15.00 (-0.07%)
F   12.54 (-0.16%)
MU   68.05 (+4.37%)
CGC   0.80 (-1.19%)
GE   110.46 (-1.67%)
DIS   80.89 (+0.95%)
AMC   8.06 (+3.47%)
PFE   33.02 (+2.90%)
PYPL   58.63 (+0.77%)
NFLX   377.72 (+0.36%)
S&P 500   4,298.30 (-0.03%)
DOW   33,563.55 (-0.31%)
QQQ   360.05 (+0.57%)
AAPL   171.70 (+0.59%)
MSFT   317.94 (+1.37%)
META   304.76 (+0.26%)
GOOGL   131.87 (-0.33%)
AMZN   127.76 (+1.41%)
TSLA   251.87 (+2.23%)
NVDA   436.98 (+1.41%)
NIO   9.04 (+1.46%)
BABA   87.04 (+1.75%)
AMD   104.07 (+1.27%)
T   15.00 (-0.07%)
F   12.54 (-0.16%)
MU   68.05 (+4.37%)
CGC   0.80 (-1.19%)
GE   110.46 (-1.67%)
DIS   80.89 (+0.95%)
AMC   8.06 (+3.47%)
PFE   33.02 (+2.90%)
PYPL   58.63 (+0.77%)
NFLX   377.72 (+0.36%)
S&P 500   4,298.30 (-0.03%)
DOW   33,563.55 (-0.31%)
QQQ   360.05 (+0.57%)
AAPL   171.70 (+0.59%)
MSFT   317.94 (+1.37%)
META   304.76 (+0.26%)
GOOGL   131.87 (-0.33%)
AMZN   127.76 (+1.41%)
TSLA   251.87 (+2.23%)
NVDA   436.98 (+1.41%)
NIO   9.04 (+1.46%)
BABA   87.04 (+1.75%)
AMD   104.07 (+1.27%)
T   15.00 (-0.07%)
F   12.54 (-0.16%)
MU   68.05 (+4.37%)
CGC   0.80 (-1.19%)
GE   110.46 (-1.67%)
DIS   80.89 (+0.95%)
AMC   8.06 (+3.47%)
PFE   33.02 (+2.90%)
PYPL   58.63 (+0.77%)
NFLX   377.72 (+0.36%)
NASDAQ:PEAR

Pear Therapeutics (PEAR) Stock Forecast, Price & News

Compare
Today's Range
N/A
50-Day Range
N/A
52-Week Range
N/A
Volume
21,409 shs
Average Volume
7.75 million shs
Market Capitalization
$4.17 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$6.67

Pear Therapeutics MarketRank™ Forecast

Analyst Rating
Hold
2.25 Rating Score
Upside/​Downside
∞ Upside
$6.67 Price Target
Short Interest
N/A
Dividend Strength
N/A
Sustainability
N/A
News Sentiment
0.00mentions of Pear Therapeutics in the last 14 days
Based on 2 Articles This Week
Insider Trading
N/A
Proj. Earnings Growth
Growing
From ($0.85) to ($0.50) Per Share

Overall MarketRank

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

1.74 out of 5 stars


PEAR stock logo

About Pear Therapeutics (NASDAQ:PEAR) Stock

Pear Therapeutics, Inc., a commercial-stage healthcare company, develops and sells software-based medicines. Its commercial products are reSET for the treatment of substance use disorder related to alcohol, cannabis, cocaine, and stimulants; reSET-O for the treatment of opioid use disorder in combination with buprenorphine; and Somryst, a software-based treatment for chronic insomnia. The company is also developing a pipeline of 14 product candidates focusing on psychiatry, neurology, and outside of central nervous system therapeutic areas, such as gastrointestinal, oncology, and cardiovascular. Pear Therapeutics, Inc. was incorporated in 2013 and is based in Boston, Massachusetts.


PEAR Stock News Headlines

Pear Therapeutics, Inc. (PEARQ)
This Stock's a Sleeping Giant
The stock everyone has their eye on - discover why it's the talk of the investment world.
This Stock's a Sleeping Giant
The stock everyone has their eye on - discover why it's the talk of the investment world.
Pear Therapeutics sold for parts
Seres Therapeutics (MCRB) Gets a Buy from Chardan Capital
Pear Therapeutics Inc (PEARQ)
Chardan Capital Remains a Buy on Omega Therapeutics (OMGA)
See More Headlines
Receive PEAR Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Pear Therapeutics and its competitors with MarketBeat's FREE daily newsletter.

PEAR Company Calendar

Today
9/29/2023
Fiscal Year End
12/31/2023

Industry, Sector and Symbol

Industry
Health services
Sub-Industry
N/A
Sector
Medical
Current Symbol
NASDAQ:PEAR
Fax
N/A
Employees
300
Year Founded
N/A

Price Target and Rating

Average Stock Price Forecast
$6.67
High Stock Price Forecast
$8.00
Low Stock Price Forecast
$5.00
Consensus Rating
Hold
Rating Score (0-4)
2.25
Research Coverage
4 Analysts

Profitability

Net Income
$-75,490,000.00
Net Margins
-594.70%
Pretax Margin
-594.70%

Debt

Sales & Book Value

Annual Sales
$12.69 million
Book Value
$0.22 per share

Miscellaneous

Free Float
98,918,000
Market Cap
$4.17 million
Optionable
Not Optionable
Beta
0.45
13 Stocks Institutional Investors Won't Stop Buying Cover

Which stocks are major institutional investors including hedge funds and endowments buying in today's market? Click the link below and we'll send you MarketBeat's list of thirteen stocks that institutional investors are buying up as quickly as they can.

Get This Free Report

Key Executives

  • Dr. Corey M. McCann M.D. (Age 43)
    Ph.D., Founder, Pres, CEO & Director
    Comp: $702.45k
  • Mr. Christopher D. T. Guiffre J.D. (Age 55)
    M.B.A., MBA, CFO, COO, Treasurer & Assistant Sec.
    Comp: $564.37k
  • Ms. Julia M. Strandberg M.B.A. (Age 48)
    Chief Commercial Officer
    Comp: $582.43k
  • Mr. Ronan P. O'Brien J.D. (Age 50)
    Chief Compliance Officer, Gen. Counsel & Sec.
  • Ms. Meara Murphy
    Sr. Director of Corp. Communications
  • Dr. Yuri Maricich M.B.A. (Age 43)
    M.D., Chief Medical Officer & Head of Devel.
  • Mr. Chris Valosky M.B.A.
    VP of Sales
  • Ms. Katherine Jeffery M.Sc. (Age 56)
    Chief People Officer
  • Ms. Erin K. Brenner (Age 50)
    Chief Product Devel. Officer
  • Ms. Ellen E. Snow CPA (Age 50)
    CGMA, VP & Corp. Controller













PEAR Stock - Frequently Asked Questions

Should I buy or sell Pear Therapeutics stock right now?

4 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Pear Therapeutics in the last twelve months. There are currently 3 hold ratings and 1 buy rating for the stock. The consensus among Wall Street analysts is that investors should "hold" PEAR shares. A hold rating indicates that analysts believe investors should maintain any existing positions they have in PEAR, but not buy additional shares or sell existing shares.
View PEAR analyst ratings
or view top-rated stocks.

What is Pear Therapeutics' stock price forecast for 2023?

4 equities research analysts have issued twelve-month price objectives for Pear Therapeutics' shares. Their PEAR share price forecasts range from $5.00 to $8.00. On average, they expect the company's share price to reach $6.67 in the next twelve months.
View analysts price targets for PEAR
or view top-rated stocks among Wall Street analysts.

What is Pear Therapeutics' stock symbol?

Pear Therapeutics trades on the NASDAQ under the ticker symbol "PEAR."

How do I buy shares of Pear Therapeutics?

Shares of PEAR stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

How much money does Pear Therapeutics make?

Pear Therapeutics (NASDAQ:PEAR) has a market capitalization of $0.00 and generates $12.69 million in revenue each year. The company earns $-75,490,000.00 in net income (profit) each year or ($0.22) on an earnings per share basis.

How many employees does Pear Therapeutics have?

The company employs 300 workers across the globe.

How can I contact Pear Therapeutics?

Pear Therapeutics' mailing address is 195 CHURCH STREET 15TH FLOOR, NEW HAVEN CT, 06510. The official website for the company is peartherapeutics.com. The company can be reached via phone at 617-925-7848 or via email at meara.murphy@peartherapeutics.com.

This page (NASDAQ:PEAR) was last updated on 9/29/2023 by MarketBeat.com Staff

My Account -